Big pharma interest remains, but the mood is fast turning gloomy.
ApexOnco Front Page
Recent articles
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
Merck sees clinical setbacks in Keylynk-008, Leap-001 and Keyvibe-002.
Arvinas’s SERD appears to edge out Olema’s, but what’s the best CDK4/6 inhibitor for a phase 3 combination?
The company hopes that new edits could solve the relapse problem with allogeneic Car-Ts.
With inavolisib’s pivotal front-line win Roche reckons it can knock out Novartis’s Piqray.
Merus still hopes for a future for MCLA-129, but the doors are closing.
Jaypirca secures a CLL label, though plans to dominate will be tempered by this market’s fast-changing nature.